Computational study of human tyrosine hydroxylase mutants to uphold [4-(propan-2-yl) phenyl]carbamic acid as a potential inhibitor

Muhammad S. Nawaz, Zahida Parveen, Liyong Wang, Sajid Rashid, Muhammad Q. Fatmi, Mohammad A. Kamal

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Neurodegenerative diseases that afflict nervous system are characterized by progressive nervous system dysfunction and associated with the one-set of many diseases like Segawa’s syndrome (recessive form), autosomal recessive L-dopa-responsive dystonia, L-dopa non-responsive dystonia or progressive early-onset encephalopathy and recessive L-dopa-responsive parkinsonism. It has been reported that a number of mutations in coding regions, splice sites and promoter regions of tyrosine hydroxylase (TH) are associated with many such diseases. TH is responsible for catalyzing the conversion of L-tyrosine to L-3,4-dihydroxyphenylalanine. This reaction is considered as rate-limiting step in the biosynthesis of catecholamines, dopamine, norepinephrine and epinephrine, which has made TH an important target for drug development. In our previous study using comparative molecular docking approach, it was concluded that [4- (Propan-2-yl) Phenyl]Carbamic acid (PPCA) may serve as a potential inhibitor. By further extending, our focus is to determine the binding affinities of PPCA and mutated TH. 3D structures of mutated TH were predicted and subjected to molecular docking studies. PPCA was found to bind in the deep narrow groove lined with polar and aromatic amino acids in 14 out of 17 mutants under study (R202H, L205P, H215Y, G216S, T245P, F278P, T283M, R297W, R306H, C328F, A345V, L356M, T368M, Q381K, P461L, T463M and D467G). Our results corroborate efficient binding of PPCA with normal and mutated TH, indicating that PPCA might be a strong therapeutic candidate for the management of Parkinson’s disease and other related disorders. It may be a valuable target for evaluation in preclinical models.

Original languageEnglish
Pages (from-to)1169-1174
Number of pages6
JournalCNS and Neurological Disorders - Drug Targets
Volume13
Issue number7
StatePublished - Jan 1 2014

Fingerprint

Tyrosine 3-Monooxygenase
Levodopa
Nervous System
Aromatic Amino Acids
Parkinsonian Disorders
Brain Diseases
Genetic Promoter Regions
Neurodegenerative Diseases
Epinephrine
Catecholamines
Parkinson Disease
Tyrosine
carbamic acid
Dopamine
Norepinephrine
Mutation
Pharmaceutical Preparations

Keywords

  • Bioinformatics
  • Docking
  • Mutation
  • Parkinson’s disease
  • Tyrosine hydroxylase

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology

Cite this

Computational study of human tyrosine hydroxylase mutants to uphold [4-(propan-2-yl) phenyl]carbamic acid as a potential inhibitor. / Nawaz, Muhammad S.; Parveen, Zahida; Wang, Liyong; Rashid, Sajid; Fatmi, Muhammad Q.; Kamal, Mohammad A.

In: CNS and Neurological Disorders - Drug Targets, Vol. 13, No. 7, 01.01.2014, p. 1169-1174.

Research output: Contribution to journalArticle

Nawaz, Muhammad S. ; Parveen, Zahida ; Wang, Liyong ; Rashid, Sajid ; Fatmi, Muhammad Q. ; Kamal, Mohammad A. / Computational study of human tyrosine hydroxylase mutants to uphold [4-(propan-2-yl) phenyl]carbamic acid as a potential inhibitor. In: CNS and Neurological Disorders - Drug Targets. 2014 ; Vol. 13, No. 7. pp. 1169-1174.
@article{9ef69f14e83c40c7808c7955dac24b50,
title = "Computational study of human tyrosine hydroxylase mutants to uphold [4-(propan-2-yl) phenyl]carbamic acid as a potential inhibitor",
abstract = "Neurodegenerative diseases that afflict nervous system are characterized by progressive nervous system dysfunction and associated with the one-set of many diseases like Segawa’s syndrome (recessive form), autosomal recessive L-dopa-responsive dystonia, L-dopa non-responsive dystonia or progressive early-onset encephalopathy and recessive L-dopa-responsive parkinsonism. It has been reported that a number of mutations in coding regions, splice sites and promoter regions of tyrosine hydroxylase (TH) are associated with many such diseases. TH is responsible for catalyzing the conversion of L-tyrosine to L-3,4-dihydroxyphenylalanine. This reaction is considered as rate-limiting step in the biosynthesis of catecholamines, dopamine, norepinephrine and epinephrine, which has made TH an important target for drug development. In our previous study using comparative molecular docking approach, it was concluded that [4- (Propan-2-yl) Phenyl]Carbamic acid (PPCA) may serve as a potential inhibitor. By further extending, our focus is to determine the binding affinities of PPCA and mutated TH. 3D structures of mutated TH were predicted and subjected to molecular docking studies. PPCA was found to bind in the deep narrow groove lined with polar and aromatic amino acids in 14 out of 17 mutants under study (R202H, L205P, H215Y, G216S, T245P, F278P, T283M, R297W, R306H, C328F, A345V, L356M, T368M, Q381K, P461L, T463M and D467G). Our results corroborate efficient binding of PPCA with normal and mutated TH, indicating that PPCA might be a strong therapeutic candidate for the management of Parkinson’s disease and other related disorders. It may be a valuable target for evaluation in preclinical models.",
keywords = "Bioinformatics, Docking, Mutation, Parkinson’s disease, Tyrosine hydroxylase",
author = "Nawaz, {Muhammad S.} and Zahida Parveen and Liyong Wang and Sajid Rashid and Fatmi, {Muhammad Q.} and Kamal, {Mohammad A.}",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "13",
pages = "1169--1174",
journal = "CNS and Neurological Disorders - Drug Targets",
issn = "1871-5273",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Computational study of human tyrosine hydroxylase mutants to uphold [4-(propan-2-yl) phenyl]carbamic acid as a potential inhibitor

AU - Nawaz, Muhammad S.

AU - Parveen, Zahida

AU - Wang, Liyong

AU - Rashid, Sajid

AU - Fatmi, Muhammad Q.

AU - Kamal, Mohammad A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Neurodegenerative diseases that afflict nervous system are characterized by progressive nervous system dysfunction and associated with the one-set of many diseases like Segawa’s syndrome (recessive form), autosomal recessive L-dopa-responsive dystonia, L-dopa non-responsive dystonia or progressive early-onset encephalopathy and recessive L-dopa-responsive parkinsonism. It has been reported that a number of mutations in coding regions, splice sites and promoter regions of tyrosine hydroxylase (TH) are associated with many such diseases. TH is responsible for catalyzing the conversion of L-tyrosine to L-3,4-dihydroxyphenylalanine. This reaction is considered as rate-limiting step in the biosynthesis of catecholamines, dopamine, norepinephrine and epinephrine, which has made TH an important target for drug development. In our previous study using comparative molecular docking approach, it was concluded that [4- (Propan-2-yl) Phenyl]Carbamic acid (PPCA) may serve as a potential inhibitor. By further extending, our focus is to determine the binding affinities of PPCA and mutated TH. 3D structures of mutated TH were predicted and subjected to molecular docking studies. PPCA was found to bind in the deep narrow groove lined with polar and aromatic amino acids in 14 out of 17 mutants under study (R202H, L205P, H215Y, G216S, T245P, F278P, T283M, R297W, R306H, C328F, A345V, L356M, T368M, Q381K, P461L, T463M and D467G). Our results corroborate efficient binding of PPCA with normal and mutated TH, indicating that PPCA might be a strong therapeutic candidate for the management of Parkinson’s disease and other related disorders. It may be a valuable target for evaluation in preclinical models.

AB - Neurodegenerative diseases that afflict nervous system are characterized by progressive nervous system dysfunction and associated with the one-set of many diseases like Segawa’s syndrome (recessive form), autosomal recessive L-dopa-responsive dystonia, L-dopa non-responsive dystonia or progressive early-onset encephalopathy and recessive L-dopa-responsive parkinsonism. It has been reported that a number of mutations in coding regions, splice sites and promoter regions of tyrosine hydroxylase (TH) are associated with many such diseases. TH is responsible for catalyzing the conversion of L-tyrosine to L-3,4-dihydroxyphenylalanine. This reaction is considered as rate-limiting step in the biosynthesis of catecholamines, dopamine, norepinephrine and epinephrine, which has made TH an important target for drug development. In our previous study using comparative molecular docking approach, it was concluded that [4- (Propan-2-yl) Phenyl]Carbamic acid (PPCA) may serve as a potential inhibitor. By further extending, our focus is to determine the binding affinities of PPCA and mutated TH. 3D structures of mutated TH were predicted and subjected to molecular docking studies. PPCA was found to bind in the deep narrow groove lined with polar and aromatic amino acids in 14 out of 17 mutants under study (R202H, L205P, H215Y, G216S, T245P, F278P, T283M, R297W, R306H, C328F, A345V, L356M, T368M, Q381K, P461L, T463M and D467G). Our results corroborate efficient binding of PPCA with normal and mutated TH, indicating that PPCA might be a strong therapeutic candidate for the management of Parkinson’s disease and other related disorders. It may be a valuable target for evaluation in preclinical models.

KW - Bioinformatics

KW - Docking

KW - Mutation

KW - Parkinson’s disease

KW - Tyrosine hydroxylase

UR - http://www.scopus.com/inward/record.url?scp=84911431158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911431158&partnerID=8YFLogxK

M3 - Article

C2 - 25230230

AN - SCOPUS:84911431158

VL - 13

SP - 1169

EP - 1174

JO - CNS and Neurological Disorders - Drug Targets

JF - CNS and Neurological Disorders - Drug Targets

SN - 1871-5273

IS - 7

ER -